Highlights & Basics
- Peripheral arterial disease (PAD) is most commonly caused by atherosclerosis.
- Most patients are asymptomatic.
- Patients require aggressive risk factor control.
- Long-term patency of lower-extremity revascularization should be monitored with a surveillance program.
- First line of therapy for patients with lifestyle-limiting claudication is a supervised 12-week exercise program and medication. Revascularization should be considered if these therapies fail.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Wound
Ischemia (ABI: ankle-brachial index; TP: toe pressure; TcPO2: transcutaneous oximetry)
Foot infection (PACO2: partial pressure of arterial carbon dioxide; SIRS: systemic inflammatory response syndrome)
Clinical stages (major limb amputation risk) based on Wound, Ischemia, and foot Infection (WIfI) classification
Citations
Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024 Sep 29;45(36):3538-700.[Abstract][Full Text]
Writing Committee Members; Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jun 18;83(24):2497-604.[Abstract][Full Text]
Norgren L, Hiatt WR, Dormandy JA, et al; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5-67.[Abstract][Full Text]
Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014 Jan;59(1):220-34;e1-2.[Abstract][Full Text]
1. Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024 Sep 29;45(36):3538-700.[Abstract][Full Text]
2. Writing Committee Members; Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jun 18;83(24):2497-604.[Abstract][Full Text]
3. Norgren L, Hiatt WR, Dormandy JA, et al; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5-67.[Abstract][Full Text]
4. Allison MA, Armstrong DG, Goodney PP, et al. Health disparities in peripheral artery disease: a scientific statement from the American Heart Association. Circulation. 2023 Jul 18;148(3):286-96.[Abstract][Full Text]
5. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013 Oct 19;382(9901):1329-40. [Abstract]
6. Kim ESH, Arya S, Bryce Y, et al. Sex differences in peripheral vascular disease: a scientific statement from the American Heart Association. Circulation. 11 Mar 2025 [Epub ahead of print].[Abstract][Full Text]
7. Watson K, Watson BD, Pater KS. Peripheral arterial disease: a review of disease awareness and management. Am J Geriatr Pharmacother. 2006 Dec;4(4):365-79.[Abstract]
8. Abaraogu UO, Ezenwankwo EF, Dall PM, et al. Living a burdensome and demanding life: A qualitative systematic review of the patients experiences of peripheral arterial disease. PLoS One. 2018 Nov 15;13(11):e0207456.[Abstract][Full Text]
9. Rajagopalan S. Approach to and management of intermittent claudication. In: Rajagopalan S, Mukherjee D, Mohler ER, eds. Manual of vascular diseases. Philadelphia, PA: Lippincott, Williams and Wilkins; 2005:70-87.
10. Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J. 1999 Mar;20(5):344-53.[Abstract][Full Text]
11. Youssef F, Gupta P, Mikhailidis DP, et al. Risk modification in patients with peripheral arterial disease: a retrospective survey. Angiology. 2005 May-Jun;56(3):279-87.[Abstract]
12. Paraskevas KI, Papas TT, Pavlidis P, et al. The importance of conservative measures in peripheral arterial disease: an update. Angiology. 2008 Oct-Nov;59(5):529-33. [Abstract]
13. Ostchega Y, Paulose-Ram R, Dillon CF, et al. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc. 2007 Apr;55(4):583-9.[Abstract]
14. Willigendael EM, Teijink JA, Bartelink ML, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004 Dec;40(6):1158-65.[Abstract]
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 Sep 12;352(9131):837-53.[Abstract]
16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Nov 7;352(9139):1558.[Abstract]
17. Andersen CA, Roukis TS. The diabetic foot. Surg Clin North Am. 2007 Oct;87(5):1149-77;x.[Abstract]
18. Clement DL, De Buyzere ML, Duprez DA. Hypertension in peripheral arterial disease. Curr Pharm Des. 2004;10(29):3615-20.[Abstract]
19. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015 Apr 24;116(9):1509-26. [Abstract]
20. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997 Jul 1;96(1):44-9. [Abstract]
21. Joosten MM, Pai JK, Bertoia ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012 Oct 24;308(16):1660-7. [Abstract]
22. Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev. 2013;(12):CD003075. [Abstract][Full Text]
23. Thomas Manapurathe D, Krishna SM, Dewdney B, et al. Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: a meta-analysis of randomised controlled trials. PLoS One. 2017 Jun 2;12(6):e0178713. [Abstract][Full Text]
24. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):145-53.[Abstract][Full Text]
25. Mehler PS, Coll JR, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003 Feb 11;107(5):753-6.[Abstract][Full Text]
26. Harris SK, Roos MG, Landry GJ. Statin use in patients with peripheral arterial disease. J Vasc Surg. 2016 Dec;64(6):1881-8. [Abstract]
27. Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007;(4):CD000123.[Abstract][Full Text]
28. Stoekenbroek RM, Boekholdt SM, Fayyad R, et al. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart. 2015 Mar;101(5):356-62.[Abstract]
29. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004 Aug 10;110(6):738-43. [Abstract]
30. Lane R, Harwood A, Watson L, et al. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017;(12):CD000990. [Abstract][Full Text]
31. Serra R, Bracale UM, Ielapi N, et al. The impact of chronic kidney disease on peripheral artery disease and peripheral revascularization. Int J Gen Med. 2021 Jul 23;14:3749-59.[Abstract][Full Text]
32. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998 Feb 10;97(5):425-8.[Abstract][Full Text]
33. Andras A, Stansby G, Hansrani M. Homocysteine lowering interventions for peripheral arterial disease and bypass grafts. Cochrane Database Syst Rev. 2013;(7):CD003285. [Abstract][Full Text]
34. Wang H, Wu P, Jiang D, et al. Relationship between serum homocysteine, fibrinogen, lipoprotein-a level, and peripheral arterial disease: a dose-response meta-analysis. Eur J Med Res. 2022 Nov 21;27(1):261.[Abstract][Full Text]
35. Małecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century - a new face of disease. Atherosclerosis. 2009 Oct;206(2):328-34.[Abstract]
36. Esfahani F, Rooholamini SA, Azadeh B, et al. Arterial fibrodysplasia: a regional cause of peripheral occlusive vascular disease. Angiology. 1989 Feb;40(2):108-13.[Abstract]
37. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-e646.[Abstract][Full Text]
38. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1223-49.[Abstract][Full Text]
39. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-337.[Abstract][Full Text]
40. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021 May 25;143(21):e984-e1010.[Abstract][Full Text]
41. Mangione CM, Barry MJ, Nicholson WK, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2022 Aug 23;328(8):746-53.[Abstract][Full Text]
42. US Preventive Services Task Force; Davidson KW, Barry MJ, et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. 2022 Apr 26;327(16):1577-84.[Abstract][Full Text]
43. American College of Radiology. ACR appropriateness criteria: management of iliac artery occlusive disease. 2024 [internet publication].[Full Text]
44. McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004 Jul 28;292(4):453-61.[Abstract][Full Text]
45. National Institute for Health and Care Excellence. Peripheral arterial disease: diagnosis and management. Dec 2020 [internet publication].[Full Text]
46. Paraskevas KI, Kotsikoris I, Koupidis SA, et al. Ankle-brachial index: a marker of both peripheral arterial disease and systemic atherosclerosis as well as a predictor of vascular events. Angiology. 2010 Aug;61(6):521-3.[Abstract]
47. American College of Radiology. ACR appropriateness criteria: lower extremity arterial claudication - imaging assessment for revascularization. 2022 [internet publication].[Full Text]
48. American College of Radiology. ACR appropriateness criteria: sudden onset of cold, painful leg. 2023 [internet publication].[Full Text]
49. Depalma RG. Impotence in vascular disease: relationship to vascular surgery. Br J Surg. 1982 Jun;69(suppl):S14-S16.[Abstract]
50. Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014 Jan;59(1):220-34;e1-2.[Abstract][Full Text]
51. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000 Jan;31(1 Pt 2):S1-296.[Abstract]
52. TASC Steering Committee; Jaff MR, White CJ, Hiatt WR, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II). Vasc Med. 2015 Oct;20(5):465-78. [Abstract]
53. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248. [Abstract][Full Text]
54. Anand SS, Bosch J, Eikelboom JW, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):219-29. [Abstract][Full Text]
55. Smolderen KG, Ujueta F, Buckley Behan D, et al. Understanding the pain experience and treatment considerations along the spectrum of peripheral artery disease: a scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes. 2025 Mar;18(3):e000135.[Abstract][Full Text]
56. Razavi MK, Lee DS, Hofmann LV. Catheter-directed thrombolytic therapy for limb ischemia: current status and controversies. J Vasc Interv Radiol. 2004 Jan;15(1 Pt 1):13-23.[Abstract]
57. Broderick C, Patel JV. Infusion techniques for peripheral arterial thrombolysis. Cochrane Database Syst Rev. 2021 Nov 17;11:CD000985.[Abstract][Full Text]
58. Robertson I, Kessel DO, Berridge DC. Fibrinolytic agents for peripheral arterial occlusion. Cochrane Database Syst Rev. 2013 Dec 19;(12):CD001099.[Abstract][Full Text]
59. Guidon M, McGee H. Exercise-based interventions and health-related quality of life in intermittent claudication: a 20-year (1989-2008) review. Eur J Cardiovasc Prev Rehabil. 2010 Apr;17(2):140-54. [Abstract]
60. Mays RJ, Hiatt WR, Casserly IP, et al. Community-based walking exercise for peripheral artery disease: an exploratory pilot study. Vasc Med. 2015 Aug;20(4):339-47. [Abstract]
61. Mangiafico RA, Fiore CE. Current management of intermittent claudication: the role of pharmacological and nonpharmacological symptom-directed therapies. Curr Vasc Pharmacol. 2009 Jul;7(3):394-413.[Abstract]
62. Pande RL, Hiatt WR, Zhang P, et al. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med. 2010 Jun;15(3):181-8. [Abstract][Full Text]
63. Brown T, Forster RB, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2021 Jun 30;6(6):CD003748.[Abstract][Full Text]
64. Warner CJ, Greaves SW, Larson RJ, et al. Cilostazol is associated with improved outcomes after peripheral endovascular interventions. J Vasc Surg. 2014 Jun;59(6):1607-14.[Abstract]
65. Iida O, Yokoi H, Soga Y, et al; STOP-IC investigators. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013 Jun 11;127(23):2307-15.[Abstract][Full Text]
66. Fakhry F, Fokkenrood HJ, Spronk S, et al. Endovascular revascularisation versus conservative management for intermittent claudication. Cochrane Database Syst Rev. 2018 Mar 8;(3):CD010512.[Abstract][Full Text]
67. Malgor RD, Alahdab F, Elraiyah TA, et al. A systematic review of treatment of intermittent claudication in the lower extremities. Vasc Surg. 2015;61:54S-73S.[Abstract]
68. Kamoen V, Vander Stichele R, Campens L, et al. Propionyl-L-carnitine for intermittent claudication. Cochrane Database Syst Rev. 2021 Dec 26;12(12):CD010117.[Abstract][Full Text]
69. Nicolaï SP, Kruidenier LM, Bendermacher BL, et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev. 2013;(6):CD006888.[Abstract][Full Text]
70. Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev. 2013;(2):CD004001.[Abstract][Full Text]
71. Liu Y, Xu Y, Fang F, et al. Therapeutic efficacy of stem cell-based therapy in peripheral arterial disease: a meta-analysis. PLoS One. 2015 Apr 29;10(4):e0125032. [Abstract]
72. Rigato M, Monami M, Fadini GP. Autologous cell therapy for peripheral arterial disease: systematic review and meta-analysis of randomized, nonrandomized, and noncontrolled studies. Circ Res. 2017 Apr 14;120(8):1326-40. [Abstract]
73. Bachoo P, Thorpe PA, Maxwell H, et al. Endovascular stents for intermittent claudication. Cochrane Database Syst Rev. 2010;(1):CD003228.[Abstract][Full Text]
74. Chowdhury MM, McLain AD, Twine CP. Angioplasty versus bare metal stenting for superficial femoral artery lesions. Cochrane Database Syst Rev. 2014;(6):CD006767.[Abstract][Full Text]
75. Nguyen BN, Amdur RL, Abugideiri M, et al. Postoperative complications after common femoral endarterectomy. J Vasc Surg. 2015 Jun;61(6):1489-94.[Abstract]
76. Reifsnyder T, Arhuidese IJ, Hicks CW, et al. Contemporary outcomes for open infrainguinal bypass in the endovascular era. Ann Vasc Surg. 2016 Jan;30:52-8.[Abstract]
77. Bedenis R, Lethaby A, Maxwell H, et al. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev. 2015;(2):CD000535.[Abstract][Full Text]
78. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020 May 21;382(21):1994-2004.[Abstract][Full Text]
79. Debus ES, Nehler MR, Govsyeyev N, et al. Effect of rivaroxaban and aspirin in patients with peripheral artery disease undergoing surgical revascularization: insights from the VOYAGER PAD trial. Circulation. 2021 Oct 5;144(14):1104-16.[Abstract][Full Text]
80. Abu Dabrh AM, Steffen MW, Asi N, et al. Bypass surgery versus endovascular interventions in severe or critical limb ischemia. J Vasc Surg. 2016 Jan;63(1):244-53.[Abstract][Full Text]
81. Hsu CC, Kwan GN, Singh D, et al. Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia. Cochrane Database Syst Rev. 2018 Dec 8;(12):CD009195.[Abstract][Full Text]
82. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019 Nov-Dec;13(6):860-72.[Abstract][Full Text]
83. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2024 Jan 2;149(1):e1-56.[Abstract][Full Text]
84. Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Feb 9;77(5):629-58.[Abstract][Full Text]
85. Basili S, Raparelli V, Vestri A, et al. Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis. Thromb Haemost. 2010 Apr;103(4):766-73. [Abstract]
86. Li L, Geraghty OC, Mehta Z, et al. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017 Jul 29;390(10093):490-9. [Abstract]
87. Kayssi A1, Al-Atassi T, Oreopoulos G, et al. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev. 2016;(8):CD011319.[Abstract][Full Text]
88. Antoniou GA, Georgiadis GS, Antoniou SA, et al. Bypass surgery for chronic lower limb ischaemia. Cochrane Database Syst Rev. 2017;(4):CD002000. [Abstract][Full Text]
89. Abu Dabrh AM, Steffen MW, Asi N, et al. Nonrevascularization-based treatments in patients with severe or critical limb ischemia. J Vasc Surg. 2015 Nov;62(5):1330-9.[Abstract]
90. Paraskevas KI, Mikhailidis DP. Angiogenesis: a promising treatment option for peripheral arterial disease. Curr Vasc Pharmacol. 2008Apr;6(2):78-80.[Abstract]
91. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease: meta-analysis and systematic review of the literature. Atherosclerosis. 2010 Mar;209(1):10-7.[Abstract]
92. Moazzami B, Mohammadpour Z, Zabala ZE, et al. Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev. 2022 Jul 8;7:CD008347.[Abstract][Full Text]
93. Teraa M, Sprengers RW, van der Graaf Y, et al. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg. 2013 Dec;258(6):922-9.[Abstract]
94. Managed Healthcare Executive. FDA approves first drug-coated angioplasty balloon catheter. Oct 2014 [internet publication].[Full Text]
95. US Food and Drug Administration. Medtronic IN.PACT Admiral paclitaxel-coated PTA balloon catheter - P140010. Dec 2014 [internet publication].[Full Text]
96. Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015 Jul 9;373(2):145-53.[Abstract][Full Text]
97. Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015 Feb 3;131(5):495-502.[Abstract][Full Text]
98. Kayssi A, Al-Jundi W, Papia G, et al. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries. Cochrane Database Syst Rev. 2019 Jan 26;(1):CD012510.[Abstract][Full Text]
99. Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018 Dec 18;7(24):e011245.[Abstract][Full Text]
100. US Food and Drug Administration. UPDATE: treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality. Aug 2019 [internet publication].
101. Gryka RJ, Buckley LF, Anderson SM. Vorapaxar: the current role and future directions of a novel protease-activated receptor antagonist for risk reduction in atherosclerotic disease. Drugs R D. 2017 Mar;17(1):65-72. [Abstract]
102. Tepe G, Brodmann M, Werner M, et al. Intravascular lithotripsy for peripheral artery calcification: 30-day outcomes from the randomized Disrupt PAD III trial. JACC Cardiovasc Interv. 2021 Jun 28;14(12):1352-61.[Abstract][Full Text]
103. Tepe G, Brodmann M, Bachinsky W, et al. Intravascular lithotripsy for peripheral artery calcification: mid-term outcomes from the randomized Disrupt PAD III trial. J Soc Cardiovasc Angiogr Interv. 2022 Jul-Aug;1(4):100341.[Abstract][Full Text]
104. National Institute for Health and Care Excellence. Intravascular lithotripsy for calcified arteries in peripheral arterial disease. Jan 2024 [internet publication].[Full Text]
105. Primary Panel:., Abramson BL, Al-Omran M, et al. Canadian Cardiovascular Society 2022 guidelines for peripheral arterial disease. Can J Cardiol. 2022 May;38(5):560-87.[Abstract][Full Text]
106. Bailey SR, Beckman JA, Dao TD, et al. ACC/AHA/SCAI/SIR/SVM 2018 appropriate use criteria for peripheral artery intervention: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine. J Am Coll Cardiol. 2019 Jan 22;73(2):214-37.[Abstract][Full Text]
107. Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019 Jul;58(1s):S1-S109.e33.[Abstract][Full Text]
108. Aboyans V, Bauersachs R, Mazzolai L, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021 Oct 14;42(39):4013-24.[Abstract][Full Text]
109. Davies MG. Criticial limb ischemia: epidemiology. Methodist Debakey Cardiovasc J. 2012 Oct-Dec;8(4):10-4. [Abstract]
110. Aday AW, Gutierrez JA. Antiplatelet therapy following peripheral arterial interventions: the choice is yours. Circ Cardiovasc Interv. 2020 Aug;13(8):e009727.[Abstract][Full Text]
